izpis_h1_title_alt

Multiple omics levels of chronic lymphocytic leukemia
ID Turk, Aleksander (Author), ID Čeh, Eva (Author), ID Calin, George Adrian (Author), ID Kunej, Tanja (Author)

.pdfPDF - Presentation file, Download (1,66 MB)
MD5: 1811DA7A7934367F0F43AE44B0CE5AA4
URLURL - Source URL, Visit https://www.nature.com/articles/s41420-024-02068-2#Sec7 This link opens in a new window

Abstract
Chronic lymphocytic leukemia (CLL) is a lymphoproliferative malignancy characterized by the proliferation of functionally mature but incompetent B cells. It is the most prevalent type of leukemia in Western populations, accounting for approximately 25% of new leukemia cases. While recent advances, such as ibrutinib and venetoclax treatment have improved patient outlook, aggressive forms of CLL such as Richter transformation still pose a significant challenge. This discrepancy may be due to the heterogeneity of factors contributing to CLL development at multiple -omics levels. However, information on the omics of CLL is fragmented, hindering multi-omics-based research into potential treatment options. To address this, we aggregated and presented a selection of important aspects of various omics levels of the disease in this review. The purpose of the present literature analysis is to portray examples of CLL studies from different omics levels, including genomics, epigenomics, transcriptomics, epitranscriptomics, proteomics, epiproteomics, metabolomics, glycomics and lipidomics, as well as those identified by multi-omics approaches. The review includes the list of 102 CLL-associated genes with relevant genomics information. While single-omics studies yield substantial and useful data, they omit a significant level of complex biological interplay present in the disease. As multi-omics studies integrate several different layers of data, they may be better suited for complex diseases such as CLL and have thus far yielded promising results. Future multi-omics studies may assist clinicians in improved treatment choices based on CLL subtypes as well as allow the identification of novel biomarkers and targets for treatments.

Language:English
Keywords:genetics, genomics, omics, medicine, chronic lymphocytic leukemia
Work type:Article
Typology:1.02 - Review Article
Organization:BF - Biotechnical Faculty
Publication status:Published
Publication version:Version of Record
Year:2024
Number of pages:14 str.
Numbering:Vol. 10, art. 293
PID:20.500.12556/RUL-159636 This link opens in a new window
UDC:575:616
ISSN on article:2058-7716
DOI:10.1038/s41420-024-02068-2 This link opens in a new window
COBISS.SI-ID:199666947 This link opens in a new window
Publication date in RUL:17.07.2024
Views:18
Downloads:3
Metadata:XML RDF-CHPDL DC-XML DC-RDF
:
Copy citation
Share:Bookmark and Share

Record is a part of a journal

Title:Cell death discovery
Publisher:Nature Publishing Group
ISSN:2058-7716
COBISS.SI-ID:284185344 This link opens in a new window

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.

Secondary language

Language:Slovenian
Keywords:genetika, genomika, omike, medicina, kronična limfocitna levkemija

Projects

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:P4-0220
Name:Primerjalna genomika in genomska biodiverziteta

Similar documents

Similar works from RUL:
Similar works from other Slovenian collections:

Back